Simultaneous Portal and Hepatic Vein Versus Portal Vein Embolizations for Hypertrophy of the Future Liver Remnant

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-04-29

Study Completion Date

2024-10-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The hypothesis is that liver venous deprivation (LVD) could strongly improve hypertrophy of the future remnant liver (FRL) at 3 weeks, as compared to portal vein embolization (PVE) in patient with liver metastases from colo-rectal origin considered as resectable.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of PVE on Patient's Long-term Survival, Complications and Cancer Recurrence.

NCT03168230

Liver Cancer Liver Metastases

COMPLETED

Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by Chemotherapy

NCT02597348

Liver Metastasis Colorectal Cancer Metastasis

ACTIVE_NOT_RECRUITING NA

Deportalization, Venous Deprivation, Venous Congestion

NCT03995459

Malignant Liver Tumor

COMPLETED

Portal Vein Thrombosis Associated With Unresectable Pancreatic Cancers : a Prospective Multicentric Cohort Study

NCT04814251

Pancreatic Adenocarcinoma

UNKNOWN

DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Combined PVE/HVE

NCT04272931

Colorectal Cancer Liver Metastases

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Portal vein embolization (PVE) has been widely used to generate hypertrophy of the nonembolized lobe in patients undergoing major hepatectomy in order to prevent small-for-size remnant liver resulting in post-operative liver insufficiency.

Although PVE is a safe and effective procedure, it does not always induce sufficient hypertrophy of the future remnant liver (FRL) even after a long time. In case of insufficient liver regeneration following PVE, some authors suggested to embolize hepatic vein(s) (Hwang, Ann Surg 2009).

Interestingly, the sequential right hepatic vein embolization (HVE) after right PVE demonstrated an incremental effect on the FRL. Although attractive, this approach requires two different procedures and does not spare time as compared to PVE alone.

To shorten and optimize the phase of liver preparation before surgery,the so-called liver venous deprivation (LVD) technique that combines both PVE and HVE during the same procedure was developed.

The aim of this randomized phase II trial is to compare the percentage of change in FRL volume at 3 weeks after LVD or PVE using MRI or CT-scan.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Metastasis Colon Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

portal vein embolization

Liver preparation before major hepatectomy : portal vein embolization (PVE) in patient with liver metastases from colo-rectal origin considered as resectable.

Group Type ACTIVE_COMPARATOR

Liver preparation before major hepatectomy

Intervention Type PROCEDURE

Simultaneous portal and hepatic vein embolization versus Portal vein embolization, also called venous deprivation OR portal vein embolization.

liver venous deprivation

Liver preparation before major hepatectomy : Patients with the liver venous deprivation (LVD) technique that combines both PVE and hepatic vein embolization (HVE) during the same procedure.

Group Type EXPERIMENTAL

Liver preparation before major hepatectomy

Intervention Type PROCEDURE

Simultaneous portal and hepatic vein embolization versus Portal vein embolization, also called venous deprivation OR portal vein embolization.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Liver preparation before major hepatectomy

Simultaneous portal and hepatic vein embolization versus Portal vein embolization, also called venous deprivation OR portal vein embolization.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Liver metastases from colo-rectal origin considered as resectable (as validated by a multidisciplinary committee with at least one senior hepatic surgeon) provided sufficient FRL volume
* Percentage of FRL volume \< 30%
* Age ≥ 18 years
* General health status World Health Organisation 0,1
* Estimated life expectancy \> 3 months
* Patients whose biological parameters are :

* Platelets ≥100,000/mm3,
* Polynuclear neutrophils ≥ 1000/mm3,
* Hemoglobin≥ 9g/dL (even transfused patients can be included)
* Creatininemia \< 1.5 times the normal value
* Creatinine clearance \> 30 milliliters (mL)/min
* Bilirubinemia ≤ 1,5 times the normal value
* liver transaminases ≤ 5 times the normal value
* prothrombin rate \> 70%
* Reference liver CT-Scan or MRI done during the 30 days preceding PVE or LVD.
* Written informed consent
* National health insurance cover

Exclusion Criteria

* Patient with cirrhosis
* Presence of clinical ascites
* Ongoing participation or participation within the 21 days prior to inclusion in the study in another therapeutic trial with an experimental drug
* Serious non-stabilized disease, active uncontrolled infection or other serious underlying disorder likely to prevent the patient from receiving the treatment
* Pregnancy (betaHCG positive), breast-feeding or the absence of effective contraception for women of child-bearing age
* Contraindication for the MRI : Pacemaker or neurosensorial stimulator or implantable defibrillator, cochlear implant, ferromagnetic foreign body similar to the nervous structure.
* Allergy or contra-indication to iodine contrast agents (thyrotoxicosis, allergy to the active substance or excipients)
* Treatment with anticoagulants (heparin or AVK) that cannot be interrupted for 48 hours
* Treatment with anti-platelets that cannot be interrupted for 5 days for aspirin or Plavix
* Legal incapacity (persons in custody or under guardianship)
* Deprived of liberty Subject (by judicial or administrative decision)
* Impossibility to sign the informed consent document or to adhere to the medical follow-up of the trial for geographical, social or psychological reasons

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No